J Korean Breast Cancer Soc.
2003 Dec;6(4):255-262.
Characteristics of HER-2/neu Oncogene in Korean Women with Early-onset Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization
- Affiliations
-
- 1Department of Radiation Oncology, Soonchunhyang University, Seoul, Korea. dohochoi@hosp.sch.ac.kr
- 2Department of Surgery, Soonchunhyang University, Seoul, Korea.
- 3Department of Clinical Pathology, Soonchunhyang University, Seoul, Korea.
- 4Department of Internal Medicine, Gacheon University, Incheon, Korea.
- 5Department of Pathology, Yale University, New Haven, CT, USA.
- 6Department of Therapeutic Radiology, Yale University, New Haven, CT, USA.
Abstract
- PURPOSE
The purpose of this work was to investigate the prognostic significance of of HER-2/neu (HER-2) oncogene protein overexpression in Korean women with early-onset breast cancer by immunohistochemistry. Furthermore, the results of the test were correlated with HER-2 oncogene gene amplification assessed by fluorescence in situ hybridization (FISH). METHODS: HER-2 status in 60 cases of breast cancer diagnosed at the age of 45 years or younger was investigated by a rabbit polyclonal antibody (Dako) and by applying the Hercep Test, and the results were compared with FISH analysis in all Hercep Test 2+ and 3+ specimens (28 cases) and five HER-2/neu negative specimens. RESULTS: FISH revealed that HER-2 was exclusively amplified in cases with Hercep Test 3+ (20/21). Cases with Hercep Test 3+ or FISH positive tumors were significantly associated with estrogen and progesterone receptor negative tumors. No association was found between HER-2 status and axillary node status. In univariate analysis, FISH status was significantly associated with poor prognosis, but Hercep Test status was not a significant prognostic factor. CONCLUSION: The finding of higher positive tumors and poor prognostic factor of Her-2 in Korean women with early- onset breast cancer may have potential implication for local and systemic management of breast cancer. HER-2 test may be useful for selecting systemic chemotherapy in Korean patients with early onset breast cancer. And the specific anti-HER-2 therapy will be helpful to a large proportion of Korean patients who have more tumors with HER-2 overexpression than White patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- HER-2/neu Oncogene Amplification by Chromogenic in situ Hybridization and Immunohistochemical Expression of Topoisomerase II-alpha in the Breast Cancer
- Comparing Fluorescence In Situ Hybridization and Immunohistochemistry to Determine the HER-2/neu Status in Breast Carcinoma
- HER-2/neu Oncogene Amplification by Chromogenic in situ Hybridization in 130 Breast Cancers Using Tissue Microarray and Clinical Follow-up Studies
- Amplification of the HER-2/neu Oncogene and Topoisomerase II-alpha by Chromogenic in Situ Hybridization in Breast Cancer
- Chromogenic In Situ Hybridization Analysis to Determinate HER-2/neu Status in Breast Carcinoma
